Last reviewed · How we verify
Glucomannan
At a glance
| Generic name | Glucomannan |
|---|---|
| Sponsor | Medical University of Warsaw |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Role of the Microbiome in the Response to Dietary Fibers Intake During Intermediate Fasting (NA)
- The Effect of Glucomannan Powder on Improving Gut Microbiota. (NA)
- Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes (NA)
- High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. (PHASE3)
- Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood (PHASE4)
- Measuring the Impact of MANNA s Medically Tailored Meal Program in Patients With a Non-terminal Cancer Diagnosis
- Efficacy of Dietary Fiber Supplementation (Soloways) in Patients With Specific Genetic Polymorphisms (NA)
- Hyperthyroidism as a Potential Predictive of Worse Outcome of Renal Graft
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucomannan CI brief — competitive landscape report
- Glucomannan updates RSS · CI watch RSS
- Medical University of Warsaw portfolio CI